GLP-1 drugs, a popular weight loss solution, have raised safety concerns as an increasing number of Americans opt for telehealth companies to access these medications. An NBC News and KFF Health News investigation highlights the risks associated with self-prescribing and self-administering GLP-1 drugs, particularly compounded versions, which are not reviewed by the FDA for safety. The story of Leslie Gammon, a North Carolina woman who suffered a GLP-1 overdose, underscores the dangers of inadequate oversight in telehealth settings. Gammon, who lost 18 pounds in four months with one telehealth company, switched to another after experiencing no weight loss. The new company prescribed a higher dose, leading to a severe overdose with vomiting and hospitalization. This incident, along with others identified by the investigation, highlights the need for better communication and follow-up care in telehealth settings. Doctors emphasize the importance of choosing telehealth companies that provide easy access to medical professionals and clear communication. They also advise patients to understand the differences between brand-name and compounded GLP-1 drugs, as compounded versions may be less safe and more confusing to use. The investigation calls for stronger oversight and transparency in the compounding process, especially as the demand for GLP-1 medications increases. Patients should be cautious when using telehealth options for GLP-1 drugs and prioritize safety by seeking out companies that offer clear communication and easy access to medical professionals.
